Core Viewpoint - Ark Health (6086.HK), known as the "first stock in AI chronic disease management," saw its stock price rise over 16% to HKD 4.35, reaching a nearly four-month high [1] Financial Performance - For the first half of 2025, Ark Health reported revenue of HKD 1.494 billion, a year-on-year increase of 12.9% [1] - The company achieved a net profit of HKD 12.5 million, marking a turnaround from previous losses [1] - Adjusted net profit reached a new high of HKD 17.6 million, up 16.8% year-on-year [1] Business Segments - Revenue from online retail pharmacy services amounted to HKD 864 million, showing a significant year-on-year growth of 28.2% [1] - Comprehensive medical services generated revenue of HKD 357 million, reflecting an 11.4% year-on-year increase [1] Analyst Coverage - Citigroup initiated coverage on Ark Health, highlighting the company's strong long-term doctor-patient relationships and a loyal, active paying user base [1] - The firm noted high user repurchase rates and strong willingness to pay, assigning a "Buy" rating with a target price of HKD 8.5 [1]
港股异动丨方舟健客大涨超16%，上半年经调整净利再创新高+获花旗看高至8.5港元